---
title: "Increasing non-receipt of vitamin K prophylaxis in newborns, 2019–June 2026"
id: "medrxiv-20-rising-rate-of-non-receipt-of-vitamin-k-prophylaxis-for-newborns-january-2019"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-20-rising-rate-of-non-receipt-of-vitamin-k-prophylaxis-for-newborns-january-2019"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361837v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Increasing non-receipt of vitamin K prophylaxis in newborns, 2019–June 2026
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-20-rising-rate-of-non-receipt-of-vitamin-k-prophylaxis-for-newborns-january-2019
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361837v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study used de-identified Truveta electronic health record data linking mother-child dyads to evaluate documented receipt of **vitamin K** prophylaxis at birth from January 1, 2019 through June 30, 2026. - Cohort included 1,026,375 live births to mothers aged 15–49; 995,628 infants (96.97%) had documented vitamin K administration on the birth date or the following day. - Overall non-receipt rose from an average of 2.1% during 2019–2022 to 4.3% in 2025 and 6.1% in 2026, reaching 8.10% in June 2026. - Logistic regression identified higher odds of non-receipt associated with older maternal age, non-Hispanic or Latino ethnicity, Medicaid or unknown insurance, and year of delivery. - Interrupted time series analysis around January 2026 showed no immediate step change, but a monthly decline in odds of vitamin K receipt of 10% after that point (OR 0.90; 95% CI 0.88–0.91), indicating acceleration in the trend. - Authors note that vitamin K recommendations did not change with the January vaccine schedule, suggesting the pattern may reflect broader shifts in confidence in newborn preventive care rather than policy changes. - The report calls for future studies to investigate causal mechanisms, parental decision-making, and clinical outcomes associated with increasing non-receipt. - All authors are employees and equity holders of Truveta, Inc.; data are de-identified and available to Truveta subscribers at studio.truveta.com.
## Clinical Analysis & Structured Key Points
Rising rate of non-receipt of vitamin K prophylaxis for newborns, January 2019 - June 2026 | medRxiv Skip to main content Rising rate of non-receipt of vitamin K prophylaxis for newborns, January 2019 - June 2026 View ORCID Profile Nina B Masters , View ORCID Profile Karen Gilbert Farrar , View ORCID Profile Emma Holler , Johnathan M Lancaster doi: https://doi.org/10.64898/2026.08.31.26361837 Nina B Masters Truveta Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nina B Masters For correspondence: ninam{at}truveta.com Karen Gilbert Farrar Truveta Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Karen Gilbert Farrar Emma Holler Truveta Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emma Holler Johnathan M Lancaster Truveta Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Vitamin K prophylaxis is universally recommended for newborns to prevent life threatening vitamin K deficiency bleeding. Although not on the immunization schedule, vitamin K prophylaxis is often coadministered with hepatitis B birth dose and erythromycin ophthalmic ointment, and rising hesitancy around vaccines/preventive care may spill over into vitamin K administration. Methods: We conducted a retrospective cohort study using Truveta electronic health record data with linked mother-child dyads. Live births to mothers aged 15-49 from January 1, 2019 through June 30, 2026 were included. Vitamin K administration was defined as documentation on the birth date or following day. Logistic regression assessed sociodemographic predictors of non-receipt, and interrupted time series analysis evaluated changes after January 2026. Results: Among 1,026,375 infants, 995,628 (96.97%) had documented vitamin K administration. Non-receipt increased from an average of 2.1% during 2019-2022 to 4.3% in 2025 and 6.1% in 2026, reaching 8.10% in June 2026. Older maternal age, non-Hispanic or Latino ethnicity, Medicaid or unknown insurance, and year of delivery were associated with greater odds of non-receipt. After January 2026, there was no immediate step change, but the odds of vitamin K receipt declined an additional 10% per month (OR: 0.90; 95% CI, 0.88-0.91). Conclusions: Vitamin K non-receipt increased over the study period and accelerated after January 2026. Because vitamin K recommendations were not changed by the January vaccine schedule, this association may reflect broader impacts to confidence in newborn preventive care. Future studies should examine causal mechanisms, parental decision-making, and associated clinical outcomes. Competing Interest Statement All authors are employees of Truveta Inc. and hold equity in the company. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. [SG2.1] 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data used in this study are available to Truveta subscribers and may be accessed at studio.truveta.com. Funder Information Declared Truveta, Inc. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Rising rate of non-receipt of vitamin K prophylaxis for newborns, January 2019 - June 2026 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Rising rate of non-receipt of vitamin K prophylaxis for newborns, January 2019 - June 2026 Nina B Masters , Karen Gilbert Farrar , Emma Holler , Johnathan M Lancaster medRxiv 2026.08.31.26361837; doi: https://doi.org/10.64898/2026.08.31.26361837 Share This Article: Copy Citation Tools Rising rate of non-receipt of vitamin K prophylaxis for newborns, January 2019 - June 2026 Nina B Masters , Karen Gilbert Farrar , Emma Holler , Johnathan M Lancaster medRxiv 2026.08.31.26361837; doi: https://doi.org/10.64898/2026.08.31.26361837 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (326) Cardiovascular Medicine (4770) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15835) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6983) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4982) Health Policy (1426) Health Systems and Quality Improvement (1736) Hematology (581) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16244) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7194) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3573) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5832) Public and Global Health (9691) Radiology and Imaging (2387) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1241) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Interventions to Improve Perinatal Care Access for Migrant Women Without Medical Insurance](https://medichelpline.com/clinical-feed/plos-one-18-interventions-facilitating-access-to-perinatal-care-for-migrant-women-without.md)
- [Hepatitis E Virus IgG Seropositivity and Kidney Dysfunction in US Adults](https://medichelpline.com/clinical-feed/medrxiv-3-hepatitis-e-virus-immunoglobulin-g-seropositivity-and-kidney-dysfunction-among.md)
- [Low antenatal hepatitis B testing and incomplete infant birth‑dose coverage in Nigeria’s MTCT prev](https://medichelpline.com/clinical-feed/medrxiv-6-contact-without-protection-high-antenatal-attendance-minimal-hepatitis-b.md)
- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)
- [Serum Magnesium and Risk of Spontaneous Bacterial Peritonitis and Sepsis in Hospitalized Cirrhosis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-association-of-serum-magnesium-levels-with-the-risk-of-spontaneous-bacterial.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.